RegeneRx is developing RGN-352, an injectable product for the treatment of cardiac tissue damage post-acute myocardial infarction and the management of multiple sclerosis.

RGN-352 represents a new approach to the treatment of acute heart attacks, as there is currently no pharmaceutical agent available that has shown both myocardial salvage and angiogenic properties in at-risk myocardial tissue. More specifically, preclinical studies have identified Tβ4's ability to promote cell migration, anti-apoptosis, anti-inflammation and myocardial stem cell differentiation.

Additionally, recently published data demonstrate for the first time that Tβ4 treatment of EAE mice (experimental autoimmune encephalomyelitis - an animal model for multiple sclerosis) significantly improves neurological function recovery. In addition to this functional benefit, the researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (development of cells insulating axons in the central nervous system) and remyelination (regeneration of the nerve sheath which is damaged in MS patients), the control of which are important therapeutic goals for patients with MS.

RegeneRx has successfully completed a phase 1 clinical trial in healthy subjects using an acute dosing regimen.

RGN-352 Injectable
Acute M.I.
Multiple Sclerosis